The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Why do many MM patients relapse after being treated with targeted therapy?
Gareth John Morgan, MD, FRCP, FRCPath, PhD, from the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, talks to us about the issue of multiple myeloma (MM) patients relapsing relatively quickly when treated with targeted immunotherapy and explains that this may be due to the possibility that not all tumours carry the mutation that is being targeted. He also notes that venetoclax, an antibody that can specifically target the 11;14 subtype of MM, is particularly promising and he believes that the future of MM therapy will be focused on developing more targeted strategies. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
